Alx Oncology Holdings INC 10-Q quarterly reports

ALX Oncology Holdings Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses but a strengthened cash position following recent equity raises.

ALX Oncology Holdings Inc. reported its first-quarter 2026 financial results, highlighting a significant reduction in operating expenses and a strong cash position, while continuing to advance its lead product candidate, evorpacept.

ALX Oncology reports a Q3 2025 net loss of $22.1 million, advancing evorpacept and ALX2004 programs while managing significant cash burn and facing regulatory setbacks.

ALX Oncology reported reduced Q2 2025 net losses but announced significant pipeline shifts, including abandoning a U.S. gastric cancer approval path and discontinuing an HNSCC program, while facing Nasdaq delisting risk.

ALX Oncology's Q1 2025 results reveal a net loss, pipeline prioritization, and strategic shifts following Phase 2 trial outcomes, alongside efforts to maintain Nasdaq listing compliance.

ALX Oncology's Q3 2024 report details a net loss of $30.7 million, alongside updates on clinical trials and financial position.

ALX Oncology's second quarter 2024 results show increased R&D spending and a net loss, alongside positive clinical trial updates for their lead product candidate, evorpacept.

ALX Oncology's first quarter 2024 results show increased research and development spending and a net loss, while highlighting progress in clinical trials and collaborations.